visualizations
Pratley, Richard Edwin, MD
Overview
overview
- Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.
research areas
- Behavioral Sciences
- Biochemistry & Molecular Biology
- Cardiovascular System & Cardiology
- Cell Biology
- Endocrinology & Metabolism
- Food Science & Technology
- General & Internal Medicine
- Genetics & Heredity
- Geriatrics & Gerontology
- Neurosciences & Neurology
- Nutrition & Dietetics
- Oncology
- Pharmacology & Pharmacy
- Physiology
- Respiratory System
- Science & Technology - Other Topics
- Zoology
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2024Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.15895 PMID: 39219437
-
2024Incretin mimetics and acute pancreatitis: enemy or innocent bystander?. CURRENT OPINION IN GASTROENTEROLOGY. 40:404-412.Full Text via DOI: 10.1097/MOG.0000000000001057 PMID: 38967917
-
2024Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM Study. DIABETES CARE. 47.Full Text via DOI: 10.2337/dc24-0201 PMID: 38713913
-
2024Receipt of Diabetes Specialty Care and Management Services by Older Adults With Diabetes in the US, 2015-2019: An Analysis of Medicare Fee-for-Service Claims. DIABETES CARE. 47.Full Text via DOI: 10.2337/dc23-1982 PMID: 38776523
-
2024Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. NATURE MEDICINE.Full Text via DOI: 10.1038/s41591-024-03133-0 PMID: 38914124
-
2024Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 38.Full Text via DOI: 10.1016/j.jdiacomp.2024.108783 PMID: 38870731
-
2024Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.15687 PMID: 38840474
-
202424-h energy expenditure in people with type 1 diabetes: impact on equations for clinical estimation of energy expenditure. EUROPEAN JOURNAL OF CLINICAL NUTRITION.Full Text via DOI: 10.1038/s41430-024-01446-4 PMID: 38745052
-
2024Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. DIABETES TECHNOLOGY & THERAPEUTICS.Full Text via DOI: 10.1089/dia.2023.0605 PMID: 38441906
-
2024Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review. COMMUNICATIONS MEDICINE. 4.Full Text via DOI: 10.1038/s43856-024-00478-y PMID: 38582818
-
2024Risk factors associated with cognitive performance and cognitive impairment in older adults with type 1 diabetes: Data from the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) study. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 38.Full Text via DOI: 10.1016/j.jdiacomp.2024.108739 PMID: 38564971
-
2024Dynamic associations between glucose and ecological momentary cognition in Type 1 Diabetes. NPJ DIGITAL MEDICINE. 7.Full Text via DOI: 10.1038/s41746-024-01036-5 PMID: 38499605
-
2024Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. DIABETES OBESITY & METABOLISM. 26:1714-1722.Full Text via DOI: 10.1111/dom.15479 PMID: 38317618
-
2024Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial. BMJ OPEN DIABETES RESEARCH & CARE. 12.Full Text via DOI: 10.1136/bmjdrc-2023-003613 PMID: 38350671
-
202413. Older Adults: Standards of Care in Diabetes-2024. DIABETES CARE. S244-S257.Full Text via DOI: 10.2337/dc24-S013 PMID: 38078580
-
2023Implementation of digital cognitive assessment and blood Implementation of digital cognitive assessment and blood based biomarkers for early detection in Alzheimer's disease at Adventhealth: A Davos Alzheimer's collaborative flagship site. JOURNAL OF THE NEUROLOGICAL SCIENCES.Full Text via DOI: 10.1016/j.jns.2023.121365
-
2023Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.15417 PMID: 38116691
-
2023EARLY DETECTION IN ALZHEIMER′S DISEASE AT ADVENTHEALTH: A DAVOS ALZHEIMER′S COLLABORATIVE FLAGSHIP SITE. INNOVATION IN AGING. 852-853.
-
2023Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. DIABETES RESEARCH AND CLINICAL PRACTICE. 204.Full Text via DOI: 10.1016/j.diabres.2023.110908 PMID: 37805000
-
2023Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. EUROPEAN HEART JOURNAL.Full Text via DOI: 10.1093/eurheartj/ehad639 PMID: 37864578
-
2023Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. DIABETOLOGIA.Full Text via DOI: 10.1007/s00125-023-06015-1 PMID: 37801140
-
2023Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. NATURE MEDICINE.Full Text via DOI: 10.1038/s41591-023-02502-5 PMID: 37794253
-
2023Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. COMMUNICATIONS MEDICINE.Full Text via DOI: 10.1038/s43856-023-00358-x PMID: 37794113
-
2023A causal roadmap for generating high-quality real-world evidence. JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE.Full Text via DOI: 10.1017/cts.2023.635 PMID: 37900353
-
2023Effect of ertugliflozin on body weight and HbA1cby baseline BMI: observations from VERTIS CV. DIABETOLOGIA. S349-S349.
-
2023
-
2023Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohort. AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY. 15.Full Text via DOI: 10.1016/j.ajpc.2023.100525 PMID: 37650052
-
2023
-
2023The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes. FRONTIERS IN ENDOCRINOLOGY. 14.Full Text via DOI: 10.3389/fendo.2023.1219293 PMID: 37576973
-
2023Effect of vitamin D on regression to normal glucose regulation and individual glycemic measures: A secondary analysis among participants adherent to the trial protocol in the randomized clinical trial vitamin D and type 2 diabetes (D2d) study. DIABETES RESEARCH AND CLINICAL PRACTICE. 202.Full Text via DOI: 10.1016/j.diabres.2023.110792 PMID: 37343726
-
2023
-
2023Host-diet-gut microbiome interactions influence human energy balance: a randomized clinical trial. NATURE COMMUNICATIONS. 14.Full Text via DOI: 10.1038/s41467-023-38778-x PMID: 37258525
-
2023An Overview of Diet and Physical Activity for Healthy Weight in Adolescents and Young Adults with Type 1 Diabetes: Lessons Learned from the ACT1ON Consortium. NUTRIENTS. 15.Full Text via DOI: 10.3390/nu15112500 PMID: 37299463
-
2023New-Onset Diabetes After COVID-19. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM.Full Text via DOI: 10.1210/clinem/dgad284 PMID: 37207448
-
2023Effects of Newer Antidiabetic Agents on Cardiovascular Outcomes in Older Adults: Systematic Review and Meta-analysis. METABOLISM-CLINICAL AND EXPERIMENTAL. S24-S24.Full Text via DOI: 10.1016/j.metabol.2023.155466
-
2023Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study*. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 37.Full Text via DOI: 10.1016/j.jdiacomp.2023.108475 PMID: 37104979
-
2023Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials. DIABETES TECHNOLOGY & THERAPEUTICS.Full Text via DOI: 10.1089/dia.2023.0029 PMID: 36999890
-
2023Associations of Dietary Intake with the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults with Type 1 Diabetes and Overweight or Obesity. JOURNAL OF NUTRITION. 153:1178-1188.Full Text via DOI: 10.1016/j.tjnut.2022.12.017 PMID: 36841667
-
2023
-
2023Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. KIDNEY INTERNATIONAL REPORTS. 8:746-753.Full Text via DOI: 10.1016/j.ekir.2023.01.011 PMID: 37069970
-
2023Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application. STATISTICS IN BIOPHARMACEUTICAL RESEARCH.Full Text via DOI: 10.1080/19466315.2023.2173644
-
2023Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. CIRCULATION. 147:1004-1013.Full Text via DOI: 10.1161/CIRCULATIONAHA.122.063716 PMID: 36802715
-
2023Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA. 52:355-375.Full Text via DOI: 10.1016/j.ecl.2022.10.010 PMID: 36948784
-
2023HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2062-2062.
-
2023Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV. DIABETES RESEARCH AND CLINICAL PRACTICE.Full Text via DOI: 10.1016/j.diabres.2023.110329
-
2023Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14990 PMID: 36700417
-
2023Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14965 PMID: 36594154
-
2023Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. 33:388-398.Full Text via DOI: 10.1016/j.numecd.2022.11.017 PMID: 36586772
-
2023Extracellular vesicle proteomics and phosphoproteomics identify pathways for increased risk in patients hospitalized with COVID-19 and type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE. 197.Full Text via DOI: 10.1016/j.diabres.2023.110565 PMID: 36736734
-
2023Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM.Full Text via DOI: 10.1210/clinem/dgac764 PMID: 36702781
-
2023"Nothing is linear": Characterizing the determinants and dynamics of CGM use in older adults with type 1 diabetes. DIABETES RESEARCH AND CLINICAL PRACTICE. 196.Full Text via DOI: 10.1016/j.diabres.2022.110204 PMID: 36509180
-
2023Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 37.Full Text via DOI: 10.1016/j.jdiacomp.2022.108389 PMID: 36669322
-
2023The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. NEPHROLOGY DIALYSIS TRANSPLANTATION.Full Text via DOI: 10.1093/ndt/gfad009 PMID: 36651820
-
2023Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. DIABETES OBESITY & METABOLISM. 25:1130-1135.Full Text via DOI: 10.1111/dom.14957 PMID: 36562481
-
2023Estimation of a Machine Learning-Based Decision Rule to Reduce Hypoglycemia Among Older Adults With Type 1 Diabetes: A Post Hoc Analysis of Continuous Glucose Monitoring in the WISDM Study. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY.Full Text via DOI: 10.1177/19322968221149040 PMID: 36629330
-
2022Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. DIABETES OBESITY & METABOLISM. 25:758-766.Full Text via DOI: 10.1111/dom.14923 PMID: 36394384
-
2022A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer-Associated Stellate Cell Small Extracellular Vesicles. MOLECULAR & CELLULAR PROTEOMICS. 21.Full Text via DOI: 10.1016/j.mcpro.2022.100438 PMID: 36332889
-
2022Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) Study. DIABETES TECHNOLOGY & THERAPEUTICS. 24:881-891.Full Text via DOI: 10.1089/dia.2022.0253 PMID: 35984327
-
2022Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14911 PMID: 36314293
-
2022The Intestinal Microbiota and Short-Chain Fatty Acids in Association with Advanced Metrics of Glycemia and Adiposity Among Young Adults with Type 1 Diabetes and Overweight or Obesity. CURRENT DEVELOPMENTS IN NUTRITION. 6.Full Text via DOI: 10.1093/cdn/nzac107 PMID: 36349343
-
2022Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial. EUROPEAN HEART JOURNAL. 2617-2617.
-
2022Effects of ertugliflozin on uric acid and gout-related outcomes: post hoc analyses from VERTIS CV. DIABETOLOGIA. S318-S319.
-
2022Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes. FRONTIERS IN ENDOCRINOLOGY. 13.Full Text via DOI: 10.3389/fendo.2022.955593 PMID: 36120427
-
2022Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial. CIRCULATION. 652-654.Full Text via DOI: 10.1161/CIRCULATIONAHA.121.058294 PMID: 35994565
-
2022Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. KIDNEY INTERNATIONAL REPORTS. 7:1782-1792.Full Text via DOI: 10.1016/j.ekir.2022.05.007 PMID: 35967112
-
2022The effect of vitamin D supplementation on cardiovascular risk in patients with prediabetes: A secondary analysis of the D2d study. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 36.Full Text via DOI: 10.1016/j.jdiacomp.2022.108230 PMID: 35753926
-
2022A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 979-994.Full Text via DOI: 10.1007/s11154-022-09735-8 PMID: 35838946
-
2022Assessing the Pathophysiology of Hyperglycemia in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study From the Type 1 Diabetes in Acute Pancreatitis Consortium. PANCREAS. 51:575-579.Full Text via DOI: 10.1097/MPA.0000000000002074 PMID: 36206461
-
2022Design and Rationale for the Use of Magnetic Resonance Imaging Biomarkers to Predict Diabetes After Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study From the Type 1 Diabetes in Acute Pancreatitis Consortium. PANCREAS. 51:586-592.Full Text via DOI: 10.1097/MPA.0000000000002080 PMID: 36206463
-
2022Standard Operating Procedures for Biospecimen Collection, Processing, and Storage From the Type 1 Diabetes in Acute Pancreatitis Consortium. PANCREAS. 51:593-597.Full Text via DOI: 10.1097/MPA.0000000000002077 PMID: 36206464
-
2022More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes. PEDIATRIC RESEARCH. 93:708-714.Full Text via DOI: 10.1038/s41390-022-02129-1 PMID: 35729217
-
2022Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. AMERICAN JOURNAL OF NEPHROLOGY.Full Text via DOI: 10.1159/000524889 PMID: 35691283
-
2022Closed-loop therapy in older adults with type 1 diabetes: hypoglycaemia benefits and risk stratification. LANCET HEALTHY LONGEVITY. E379-E379.PMID: 36098316
-
2022Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes.. Contemporary clinical trials. 106765.Full Text via DOI: 10.1016/j.cct.2022.106765 PMID: 35460915
-
2022Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.. Diabetes, obesity & metabolism.Full Text via DOI: 10.1111/dom.14769 PMID: 35603908
-
2022The Ile191Val Variant of the TAS1R2 Subunit of Sweet Taste Receptors Is Associated With Reduced HbA(1c) in a Human Cohort With Variable Levels of Glucose Homeostasis. FRONTIERS IN NUTRITION. 9.Full Text via DOI: 10.3389/fnut.2022.896205 PMID: 35662939
-
2022BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE. NEPHROLOGY DIALYSIS TRANSPLANTATION. I893-I894.
-
2022Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 23.Full Text via DOI: 10.3390/ijms23105779 PMID: 35628588
-
2022Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. DIABETES TECHNOLOGY & THERAPEUTICS.Full Text via DOI: 10.1089/dia.2021.0503 PMID: 35294272
-
2022Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14691 PMID: 35266296
-
2022The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. DIABETES OBESITY & METABOLISM. 24:1114-1122.Full Text via DOI: 10.1111/dom.14677 PMID: 35233908
-
2022Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. DIABETOLOGIA. 908-911.Full Text via DOI: 10.1007/s00125-021-05623-z PMID: 35238955
-
2022Can technology improve the management of older adults with type 1 diabetes? Yes, but... Comment. LANCET HEALTHY LONGEVITY. E120-E121.
-
2022Indirect treatment comparisons: Choosing the right tool for the job. DIABETES OBESITY & METABOLISM. 1180-1181.Full Text via DOI: 10.1111/dom.14664 PMID: 35129275
-
2022Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ OPEN DIABETES RESEARCH & CARE. 10.Full Text via DOI: 10.1136/bmjdrc-2021-002207 PMID: 35042751
-
2022Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.. Circulation. 565-574.Full Text via DOI: 10.1161/CIRCULATIONAHA.121.057934 PMID: 34775781
-
2022Y Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 107:230-240.Full Text via DOI: 10.1210/clinem/dgab649 PMID: 34473295
-
2021An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM.Full Text via DOI: 10.1210/clinem/dgab905 PMID: 34922383
-
2021The Ile191Val is a partial loss-of-function variant of the TAS1R2 sweet-taste receptor and is associated with reduced glucose excursions in humans. MOLECULAR METABOLISM. 54.Full Text via DOI: 10.1016/j.molmet.2021.101339 PMID: 34509698
-
2021Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ OPEN DIABETES RESEARCH & CARE. 9.Full Text via DOI: 10.1136/bmjdrc-2021-002339 PMID: 34819298
-
2021Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial. EUROPEAN HEART JOURNAL. 2650-2650.
-
2021Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. LANCET DIABETES & ENDOCRINOLOGY. 653-662.Full Text via DOI: 10.1016/S2213-8587(21)00203-5 PMID: 34425083
-
2021Effects of Ertugliflozin on Kidney End Points in Patients with Non-Albuminuric Diabetic Kidney Disease in VERTIS CV. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 262-263.
-
2021Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ OPEN DIABETES RESEARCH & CARE. 9.Full Text via DOI: 10.1136/bmjdrc-2021-002484 PMID: 34620621
-
2021Maintaining Operational Excellence During the COVID-19 Pandemic in the FLOW Trial. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. B6-B6.
-
2021
-
2021
-
2021
-
2021Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 16:1345-1354.Full Text via DOI: 10.2215/CJN.01130121 PMID: 34497110
-
2021Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV. DIABETOLOGIA. 30-31.
-
2021Twenty-four hour assessments of substrate oxidation reveal differences in metabolic flexibility in type 2 diabetes that are improved with aerobic training. DIABETOLOGIA.Full Text via DOI: 10.1007/s00125-021-05535-y PMID: 34402932
-
2021An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14497 PMID: 34286894
-
2021Cardiovascular Outcomes Trials of Incretin-Based Therapies.. Diabetes spectrum : a publication of the American Diabetes Association. 217-224.Full Text via DOI: 10.2337/ds20-0072 PMID: 34511847
-
2021Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes A Secondary Analysis of a Randomized Trial. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 16:1201-1209.Full Text via DOI: 10.2215/CJN.00420121 PMID: 34362787
-
2021Cardiovascular Outcome Trials with Glucose-Lowering Drugs. CURRENT CARDIOLOGY REPORTS.Full Text via DOI: 10.1007/s11886-021-01505-3 PMID: 34081215
-
2021Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE.Full Text via DOI: 10.1056/NEJMoa2108269 PMID: 34215025
-
2021Kidney outcomes using a sustained >= 40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. CLINICAL CARDIOLOGY.Full Text via DOI: 10.1002/clc.23665 PMID: 34129237
-
2021Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 35.Full Text via DOI: 10.1016/j.jdiacomp.2021.107884 PMID: 33610436
-
2021Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. DIABETES OBESITY & METABOLISM.Full Text via DOI: 10.1111/dom.14443 PMID: 34009708
-
2021STRONG TREATMENT EFFECT OF CONTINUOUS GLUCOSE MONITORING (CGM) IN REDUCING HYPOGLYCEMIA IRRESPECTIVE OF PREVIOUS BLOOD GLUCOSE MONITORING AMONG OLDER ADULTS WITH TYPE 1 DIABETES (T1D). DIABETES TECHNOLOGY & THERAPEUTICS. A36-A36.
-
2021Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. DIABETES OBESITY & METABOLISM. 23:1666-1671.Full Text via DOI: 10.1111/dom.14381 PMID: 33764641
-
2021Investigation of Extracellular Vesicles From SARS-CoV-2 Infected Specimens: A Safety Perspective. FRONTIERS IN IMMUNOLOGY. 12.Full Text via DOI: 10.3389/fimmu.2021.617042 PMID: 33968019
-
2021Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. DIABETES CARE. 44:1020-1026.Full Text via DOI: 10.2337/dc20-1622 PMID: 33504496
-
2021ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLOS ONE. 16.Full Text via DOI: 10.1371/journal.pone.0249038 PMID: 33765049
-
2021Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. DIABETOLOGIA. 64:1256-1267.Full Text via DOI: 10.1007/s00125-021-05407-5 PMID: 33665685
-
2021Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. DIABETES THERAPY. 12:1099-1116.Full Text via DOI: 10.1007/s13300-020-00994-9 PMID: 33660198
-
2021Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function Observations From VERTIS CV. CIRCULATION. 602-605.Full Text via DOI: 10.1161/CIRCULATIONAHA.120.051901 PMID: 33186063
-
2021A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function. CIRCULATION. 143:145-159.Full Text via DOI: 10.1161/CIRCULATIONAHA.120.049813 PMID: 33106031
-
2021High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice. MICROBIOME. 9.Full Text via DOI: 10.1186/s40168-020-00976-w PMID: 33431052
-
2021Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study.. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY. 582-592.Full Text via DOI: 10.1177/1932296819894974 PMID: 31867988
-
2020Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial. CIRCULATION. 142:2205-2215.Full Text via DOI: 10.1161/CIRCULATIONAHA.120.050255 PMID: 33026243
-
2020Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. DIABETES OBESITY & METABOLISM. 23:569-580.Full Text via DOI: 10.1111/dom.14254 PMID: 33185002
-
2020Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. DIABETES OBESITY & METABOLISM. 22:2248-2256.Full Text via DOI: 10.1111/dom.14208 PMID: 32996693
-
2020Let's Be More Sensitive-How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect beta-Cell Function in Type 2 Diabetes Comment on "Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM" by Ali et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM.Full Text via DOI: 10.1210/clinem/dgaa666 PMID: 33074334
-
2020Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). DIABETES & VASCULAR DISEASE RESEARCH. 17.Full Text via DOI: 10.1177/1479164120970933 PMID: 33280425
-
2020Design and baseline characteristics of theAMPLITUDE-Ocardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. DIABETES OBESITY & METABOLISM. 23:318-323.Full Text via DOI: 10.1111/dom.14223 PMID: 33026143
-
2020Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE. 383:1425-1435.Full Text via DOI: 10.1056/NEJMoa2004967 PMID: 32966714
-
2020Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis. JAMA CARDIOLOGY. 6:148-158.Full Text via DOI: 10.1001/jamacardio.2020.4511 PMID: 33031522
-
2020Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. PEDIATRIC DIABETES. 21:1475-1484.Full Text via DOI: 10.1111/pedi.13132 PMID: 32981192
-
2020Diabetes in ageing: pathways for developing the evidence base for clinical guidance. LANCET DIABETES & ENDOCRINOLOGY. 855-867.PMID: 32946822
-
2020Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials. DIABETES OBESITY & METABOLISM. 22:2487-2492.Full Text via DOI: 10.1111/dom.14160 PMID: 32744418
-
2020Renoprotection with semaglutide and liraglutide: Direct or indirect effects?. DIABETOLOGIA. S67-S68.
-
2020Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phaseIIIstudies. DIABETES OBESITY & METABOLISM. 22:2276-2286.Full Text via DOI: 10.1111/dom.14150 PMID: 32700421
-
2020Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from theLEADERandSUSTAIN6 clinical trials. DIABETES OBESITY & METABOLISM. 22:2193-2198.Full Text via DOI: 10.1111/dom.14140 PMID: 32643857
-
2020Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from theLEADERrandomized trial. DIABETES OBESITY & METABOLISM. 22:2077-2088.Full Text via DOI: 10.1111/dom.14126 PMID: 32618386
-
2020Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. DIABETES OBESITY & METABOLISM. 1231-1242.Full Text via DOI: 10.1111/dom.14013 PMID: 32100382
-
2020Pharmacological therapies to address obesity in type 1 diabetes. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY. 194-206.Full Text via DOI: 10.1097/MED.0000000000000555 PMID: 32618631
-
2020Risk of severe hypoglycaemia and its impact in type 2 diabetes inDEVOTE. DIABETES OBESITY & METABOLISM. 22:2241-2247.Full Text via DOI: 10.1111/dom.14049 PMID: 32250536
-
2020Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. DIABETES CARE. 43:1546-1552.Full Text via DOI: 10.2337/dc19-2251 PMID: 32366578
-
2020Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes A Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 323:2397-2406.Full Text via DOI: 10.1001/jama.2020.6928 PMID: 32543682
-
2020The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. DIABETES OBESITY & METABOLISM. 22:1690-1695.Full Text via DOI: 10.1111/dom.14079 PMID: 32372454
-
2020An improvement in skeletal muscle mitochondrial capacity with short-term aerobic training is associated with changes in Tribbles 1 expression. PHYSIOLOGICAL REPORTS. 8.Full Text via DOI: 10.14814/phy2.14416 PMID: 32562350
-
2020Reproducibility of a prediabetes classification in a contemporary population.. Metabolism open. 100031.Full Text via DOI: 10.1016/j.metop.2020.100031 PMID: 32812912
-
2020Characteristics of adult- compared to childhood-onset type 1 diabetes. DIABETIC MEDICINE.Full Text via DOI: 10.1111/dme.14314 PMID: 32353892
-
2020Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. DIABETES OBESITY & METABOLISM. 22:1537-1547.Full Text via DOI: 10.1111/dom.14063 PMID: 32314525
-
2020Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. DIABETES OBESITY & METABOLISM. 1263-1277.Full Text via DOI: 10.1111/dom.14054 PMID: 32267058
-
2020Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 105.Full Text via DOI: 10.1210/clinem/dgaa015 PMID: 31955209
-
2020GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. FRONTIERS IN ENDOCRINOLOGY.Full Text via DOI: 10.3389/fendo.2020.00178 PMID: 32308645
-
2020High residual C-peptide likely contributes to glycemic control in type 1 diabetes. JOURNAL OF CLINICAL INVESTIGATION. 130:1850-1862.Full Text via DOI: 10.1172/JCI134057 PMID: 31895699
-
2020The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. DIABETES CARE. 43:806-812.Full Text via DOI: 10.2337/dc19-1583 PMID: 32029635
-
2020Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 75:1128-1141.Full Text via DOI: 10.1016/j.jacc.2019.12.063 PMID: 32164886
-
2020BENEFIT OF CONTINUOUS GLUCOSE MONITORING (CGM) IN REDUCING HYPOGLYCEMIA IS SUSTAINED THROUGH 12 MONTHS OF USE AMONG OLDER ADULTS WITH TYPE 1 DIABETES (T1D). DIABETES TECHNOLOGY & THERAPEUTICS. A21-A22.
-
2020EFFICACY OF ORAL SEMAGLUTIDE ACCORDING TO DIABETES DURATION: AN EXPLORATORY SUBGROUP ANALYSIS OF THE PIONEER TRIAL PROGRAMME. DIABETES TECHNOLOGY & THERAPEUTICS. A185-A185.
-
2020Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. DIABETES. 69:146-157.Full Text via DOI: 10.2337/db18-1163 PMID: 31757794
-
2020Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. DIABETES CARE. 43:418-425.Full Text via DOI: 10.2337/dc19-0986 PMID: 31843946
-
2020OLDER ADULTS WITH TYPE 1 DIABETES DEMONSTRATE HIGH UTILIZATION OF CGM AND HIGH CONFIDENCE IN CGM DATA. DIABETES TECHNOLOGY & THERAPEUTICS. A71-A71.
-
2020Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ OPEN. 10.Full Text via DOI: 10.1136/bmjopen-2020-037883 PMID: 33199417
-
2019Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. CARDIOVASCULAR DIABETOLOGY. 18.Full Text via DOI: 10.1186/s12933-019-0960-8 PMID: 31729990
-
2019Endurance training remodels skeletal muscle phospholipid composition and increases intrinsic mitochondrial respiration in men with Type 2 diabetes. PHYSIOLOGICAL GENOMICS. 51:586-595.Full Text via DOI: 10.1152/physiolgenomics.00014.2019 PMID: 31588872
-
2019Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). DIABETES THERAPY. 11:53-70.Full Text via DOI: 10.1007/s13300-019-00715-x PMID: 31667706
-
2019
-
2019
-
2019Pooled analysis of the safety and efficacy of ertugliflozin in the elderly. DIABETOLOGIA. S359-S360.
-
2019The interplay of type 1 diabetes and weight management: A qualitative study exploring thematic progression from adolescence to young adulthood. PEDIATRIC DIABETES. 20:974-985.Full Text via DOI: 10.1111/pedi.12903 PMID: 31392807
-
2019Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. DIABETES OBESITY & METABOLISM. 21:2429-2439.Full Text via DOI: 10.1111/dom.13824 PMID: 31264757
-
2019Vitamin D Supplementation and Prevention of Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE. 381:520-530.Full Text via DOI: 10.1056/NEJMoa1900906 PMID: 31173679
-
2019Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. DIABETES OBESITY & METABOLISM. 21:2450-2458.Full Text via DOI: 10.1111/dom.13826 PMID: 31282028
-
2019Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. LANCET. 394:39-50.Full Text via DOI: 10.1016/S0140-6736(19)31271-1 PMID: 31186120
-
2019Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). DIABETES OBESITY & METABOLISM. 21:1625-1633.Full Text via DOI: 10.1111/dom.13699 PMID: 30850995
-
2019Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. DIABETES OBESITY & METABOLISM. 21:1745-1751.Full Text via DOI: 10.1111/dom.13698 PMID: 30851070
-
2019Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. LANCET DIABETES & ENDOCRINOLOGY. 7:515-527.Full Text via DOI: 10.1016/S2213-8587(19)30192-5 PMID: 31189517
-
2019EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. NEPHROLOGY DIALYSIS TRANSPLANTATION. 205-U715.
-
2019EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. NEPHROLOGY DIALYSIS TRANSPLANTATION. 338-338.
-
2019EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. NEPHROLOGY DIALYSIS TRANSPLANTATION.
-
2019Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). DIABETES OBESITY & METABOLISM. 21:1437-1444.Full Text via DOI: 10.1111/dom.13677 PMID: 30793465
-
2019Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data. PHARMACEUTICAL MEDICINE. 33:209-217.Full Text via DOI: 10.1007/s40290-019-00281-4 PMID: 31933292
-
2019Pioglitazone Therapy in Patients With Stroke and Prediabetes A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA NEUROLOGY. 76:526-535.Full Text via DOI: 10.1001/jamaneurol.2019.0079 PMID: 30734043
-
2019Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. ANNALS OF INTERNAL MEDICINE. 423-+.Full Text via DOI: 10.7326/M18-1569 PMID: 30508430
-
2019Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. MOLECULAR METABOLISM. 20:63-78.Full Text via DOI: 10.1016/j.molmet.2018.11.003 PMID: 30503831
-
2018Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke Post Hoc Analysis From the LEADER Trial. CIRCULATION. 138:2884-2894.Full Text via DOI: 10.1161/CIRCULATIONAHA.118.034516 PMID: 30566004
-
2018Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). AMERICAN HEART JOURNAL. 206:11-23.Full Text via DOI: 10.1016/j.ahj.2018.08.016 PMID: 30290289
-
2018Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. CURRENT DIABETES REPORTS.Full Text via DOI: 10.1007/s11892-018-1086-1 PMID: 30229352
-
2018First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. DIABETES CARE. 41:2396-2403.Full Text via DOI: 10.2337/dc18-1032 PMID: 30254083
-
2018T1R2 receptor-mediated glucose sensing in the upper intestine potentiates glucose absorption through activation of local regulatory pathways. MOLECULAR METABOLISM. 17:98-111.Full Text via DOI: 10.1016/j.molmet.2018.08.009 PMID: 30201274
-
2018Effect of liraglutide on cardiovascular outcomes in elderly patients in the LEADER trial. DIABETOLOGIA. S368-S369.
-
2018Exercise Response Variations in Skeletal Muscle PCr Recovery Rate and Insulin Sensitivity Relate to Muscle Epigenomic Profiles in Individuals With Type 2 Diabetes. DIABETES CARE. 41:2245-2254.Full Text via DOI: 10.2337/dc18-0296 PMID: 30072402
-
2018Implications of cardiovascular outcome trials with injectable antidiabetic agents. JOURNAL OF DIABETES. 801-803.Full Text via DOI: 10.1111/1753-0407.12792 PMID: 29971941
-
2018Liraglutide effects in insulin-treated patients in LEADER. DIABETOLOGIA. S563-S563.
-
2018Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. ENDOCRINE REVIEWS. 629-663.Full Text via DOI: 10.1210/er.2017-00191 PMID: 30060120
-
2018
-
2018The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. DIABETES CARE. 41:2229-2235.Full Text via DOI: 10.2337/dc18-1094 PMID: 30072400
-
2018Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. DIABETES CARE. 41:1590-1599.Full Text via DOI: 10.2337/dc18-0240 PMID: 29941495
-
2018Troponin T3 associates with DNA consensus sequence that overlaps with p53 binding motifs. EXPERIMENTAL GERONTOLOGY. 108:35-40.Full Text via DOI: 10.1016/j.exger.2018.03.012 PMID: 29596868
-
2018Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial. CIRCULATION. 2179-2183.Full Text via DOI: 10.1161/CIRCULATIONAHA.118.033898 PMID: 29760228
-
2018Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. DIABETES OBESITY & METABOLISM. 20:1193-1201.Full Text via DOI: 10.1111/dom.13215 PMID: 29316143
-
2018Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. DIABETES OBESITY & METABOLISM. 20:1111-1120.Full Text via DOI: 10.1111/dom.13194 PMID: 29266675
-
2018Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. LANCET DIABETES & ENDOCRINOLOGY. 6:275-286.Full Text via DOI: 10.1016/S2213-8587(18)30024-X PMID: 29397376
-
2018Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors. BMC CANCER. 18.Full Text via DOI: 10.1186/s12885-018-4272-2 PMID: 29587682
-
2018DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. DIABETOLOGIA. 61:58-65.Full Text via DOI: 10.1007/s00125-017-4422-0 PMID: 28913543
-
2018Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). DIABETOLOGIA. 61:48-57.Full Text via DOI: 10.1007/s00125-017-4423-z PMID: 28913575
-
2018Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). DIABETES OBESITY & METABOLISM. 20:148-156.Full Text via DOI: 10.1111/dom.13051 PMID: 28671753
-
2018Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY. 1184-1191.Full Text via DOI: 10.1177/1932296818776993 PMID: 29893144
-
2017Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control. JOURNAL OF NUTRITIONAL BIOCHEMISTRY. 49:117-122.Full Text via DOI: 10.1016/j.jnutbio.2017.08.007 PMID: 28945992
-
2017
-
2017Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. NEW ENGLAND JOURNAL OF MEDICINE. 377:723-732.Full Text via DOI: 10.1056/NEJMoa1615692 PMID: 28605603
-
2017Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps. CURRENT DIABETES REPORTS.Full Text via DOI: 10.1007/s11892-017-0892-1 PMID: 28660565
-
2017
-
2017Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.. Clinical diabetes : a publication of the American Diabetes Association. 141-153.Full Text via DOI: 10.2337/cd16-0063 PMID: 28761216
-
2017Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfall.. BMJ CASE REPORTS.Full Text via DOI: 10.1136/bcr-2017-220600 PMID: 28619742
-
2017Inhibition of sweet chemosensory receptors alters insulin responses during glucose ingestion in healthy adults: a randomized crossover interventional study. AMERICAN JOURNAL OF CLINICAL NUTRITION. 105:1001-1009.Full Text via DOI: 10.3945/ajcn.116.146001 PMID: 28251932
-
2017Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. DIABETES CARE. E47-E48.Full Text via DOI: 10.2337/dci16-0048 PMID: 28325804
-
2017Measurement of altered APP isoform expression in adipose tissue of diet-induced obese mice by absolute quantitative real-time PCR. ANIMAL CELLS AND SYSTEMS. 21:100-107.Full Text via DOI: 10.1080/19768354.2017.1290679 PMID: 30460057
-
2016LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 30:1631-1639.Full Text via DOI: 10.1016/j.jdiacomp.2016.06.001 PMID: 27320184
-
2016Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. DIABETES TECHNOLOGY & THERAPEUTICS. 671-673.Full Text via DOI: 10.1089/dia.2016.0339 PMID: 27860501
-
2016Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. DIABETES CARE. 39:1684-1692.Full Text via DOI: 10.2337/dc16-0798 PMID: 27465265
-
2016Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) DEVOTE 1. AMERICAN HEART JOURNAL. 179:175-183.Full Text via DOI: 10.1016/j.ahj.2016.06.004 PMID: 27595693
-
2016Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. SCIENTIFIC REPORTS. 6.Full Text via DOI: 10.1038/srep31479 PMID: 27558530
-
2016Comparison of two treatment approaches in older patients with type 2 diabetes (IMPERIUM). DIABETOLOGIA. S395-S396.
-
2016Effects of Glucose and Insulin on Secretion of Amyloid-beta by Human Adipose Tissue Cells. OBESITY. 24:1471-1479.Full Text via DOI: 10.1002/oby.21494 PMID: 27172814
-
2016Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox. MAYO CLINIC PROCEEDINGS. 91:858-866.Full Text via DOI: 10.1016/j.mayocp.2016.03.020 PMID: 27289411
-
2016Disruption of the sugar-sensing receptor T1R2 attenuates metabolic derangements associated with diet-induced obesity. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 310:E688-E698.Full Text via DOI: 10.1152/ajpendo.00484.2015 PMID: 26884387
-
2016Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. OBESITY. 24:820-828.Full Text via DOI: 10.1002/oby.21418 PMID: 26887289
-
2016COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. ENDOCRINE PRACTICE. 22:406-411.Full Text via DOI: 10.4158/EP15758.OR PMID: 26574791
-
2016Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. DIABETES CARE. 39:603-610.Full Text via DOI: 10.2337/dc15-1426 PMID: 26681721
-
2016Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 23:50-58.Full Text via DOI: 10.1177/2047487314544046 PMID: 25073857
-
2015Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. JOURNAL OF NUTRITIONAL BIOCHEMISTRY. 26:1599-1606.Full Text via DOI: 10.1016/j.jnutbio.2015.07.014 PMID: 26324406
-
2015Dietary sugars downregulate intestinal sweet taste receptors leading to altered glucose absorption in mice. CHEMICAL SENSES. 616-616.
-
2015The Impact of Diabetes and Diabetes Medications on Bone Health. ENDOCRINE REVIEWS. 194-213.Full Text via DOI: 10.1210/er.2012-1042 PMID: 25738213
-
2014HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. DIABETOLOGIA. 57:2475-2484.Full Text via DOI: 10.1007/s00125-014-3360-3 PMID: 25208756
-
2014A patient-centered approach to managing patients with type 2 diabetes.. The American journal of medicine. e15-e16.Full Text via DOI: 10.1016/j.amjmed.2014.10.007 PMID: 25447628
-
2014Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice. ANIMAL CELLS AND SYSTEMS. 18:219-227.Full Text via DOI: 10.1080/19768354.2014.940383
-
2014Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. DIABETES OBESITY & METABOLISM. 16:613-621.Full Text via DOI: 10.1111/dom.12258 PMID: 24400655
-
2014TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE OLDER ADULT: A REVIEW. ENDOCRINE PRACTICE. 722-736.Full Text via DOI: 10.4158/EP13192.RA PMID: 24518176
-
2014The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?. DIABETOLOGIA. 1273-1275.Full Text via DOI: 10.1007/s00125-014-3263-3 PMID: 24849569
-
2014Improved glucose tolerance with restored expression of glucose transporter 4 in C57BL/6 mice after a long period of high-fat diet feeding. ANIMAL CELLS AND SYSTEMS. 18:197-203.Full Text via DOI: 10.1080/19768354.2014.924995
-
2014Sweet Taste Receptors Regulate Basal Insulin Secretion and Contribute to Compensatory Insulin Hypersecretion During the Development of Diabetes in Male Mice. ENDOCRINOLOGY. 155:2112-2121.Full Text via DOI: 10.1210/en.2013-2015 PMID: 24712876
-
2014Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. LANCET DIABETES & ENDOCRINOLOGY. 2:289-297.Full Text via DOI: 10.1016/S2213-8587(13)70214-6 PMID: 24703047
-
2014Linagliptin use in older individuals with type 2 diabetes. CLINICAL INTERVENTIONS IN AGING. 9.Full Text via DOI: 10.2147/CIA.S62877 PMID: 25083132
-
2013Changing Patterns in the Treatment of Type 2 Diabetes Introduction. AMERICAN JOURNAL OF MEDICINE. S1-S1.Full Text via DOI: 10.1016/j.amjmed.2013.06.008 PMID: 23953073
-
2013HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus. DIABETOLOGIA. S360-S361.
-
2013The Early Treatment of Type 2 Diabetes. AMERICAN JOURNAL OF MEDICINE. S2-S9.Full Text via DOI: 10.1016/j.amjmed.2013.06.007 PMID: 23953075
-
2013Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. DIABETES OBESITY & METABOLISM. 15:668-673.Full Text via DOI: 10.1111/dom.12093 PMID: 23489301
-
2013Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). DIABETES OBESITY & METABOLISM. 15:234-240.Full Text via DOI: 10.1111/dom.12009 PMID: 22958426
-
2013LIRAGLUTIDE ACHIEVES A1C TARGETS MORE OFTEN THAN SITAGLIPTIN OR EXENATIDE WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AND A BASELINE A1C < 8.0%. ENDOCRINE PRACTICE. 19:64-72.Full Text via DOI: 10.4158/EP12232.OR PMID: 23186975
-
2012Diabetes in Older Adults. DIABETES CARE. 2650-2664.Full Text via DOI: 10.2337/dc12-1801 PMID: 23100048
-
2012Diabetes in Older Adults: A Consensus Report. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 2342-2356.Full Text via DOI: 10.1111/jgs.12035 PMID: 23106132
-
2012
-
2012Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. DIABETES CARE. 35:1986-1993.Full Text via DOI: 10.2337/dc11-2113 PMID: 22851600
-
2012Obesity and Asthma An Inflammatory Disease of Adipose Tissue Not the Airway. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 186:598-605.Full Text via DOI: 10.1164/rccm.201203-0573OC PMID: 22837379
-
2012Associations of Fatty Acids in Cerebrospinal Fluid with Peripheral Glucose Concentrations and Energy Metabolism. PLOS ONE. 7.Full Text via DOI: 10.1371/journal.pone.0041503 PMID: 22911803
-
2012Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 97:1615-1622.Full Text via DOI: 10.1210/jc.2011-2243 PMID: 22419732
-
2012Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus. POSTGRADUATE MEDICINE. 124:133-143.Full Text via DOI: 10.3810/pgm.2012.01.2526 PMID: 22314123
-
2012Measurement of Altered A beta PP Isoform Expression in Frontal Cortex of Patients with Alzheimer's Disease by Absolute Quantification Real-Time PCR. JOURNAL OF ALZHEIMERS DISEASE. 29:449-457.Full Text via DOI: 10.3233/JAD-2011-111337 PMID: 22258516
-
2011Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >= 65 and <65 Years of Age: A Pooled Analysis from Phase III Studies. AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY. 9:423-433.Full Text via DOI: 10.1016/j.amjopharm.2011.09.007 PMID: 22055210
-
2011EFFICACY OF ANTIHYPERGLYCEMIC THERAPIES AND THE INFLUENCE OF BASELINE HEMOGLOBIN A(1C): A META-ANALYSIS OF THE LIRAGLUTIDE DEVELOPMENT PROGRAM. ENDOCRINE PRACTICE. 17:906-913.PMID: 22193143
-
2011Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 128:508-U109.Full Text via DOI: 10.1016/j.jaci.2011.06.009 PMID: 21782230
-
2011FOCUS ON INCRETIN-BASED THERAPIES FOR ELDERLY PATIENTS WITH TYPE 2 DIABETES. ENDOCRINE PRACTICE. 17:20-26.
-
2011Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. CIRCULATION. 124:695-U130.Full Text via DOI: 10.1161/CIRCULATIONAHA.110.014860 PMID: 21768545
-
2011Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. CURRENT DIABETES REPORTS. 11:179-184.Full Text via DOI: 10.1007/s11892-011-0189-8 PMID: 21424395
-
2011Alternative and Complementary Treatments for Metabolic Syndrome. CURRENT DIABETES REPORTS. 11:173-178.Full Text via DOI: 10.1007/s11892-011-0184-0 PMID: 21336843
-
2011Does the metabolic syndrome carry additional risk for myocardial infarction?. Current diabetes reports. 149-50.Full Text via DOI: 10.1007/s11892-011-0181-3 PMID: 21336844
-
2011One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 65:397-407.Full Text via DOI: 10.1111/j.1742-1241.2011.02656.x PMID: 21355967
-
2011Sexually Dimorphic Diet-Induced Insulin Resistance in Obese Tissue Inhibitor of Metalloproteinase-2 (TIMP-2)-Deficient Mice. ENDOCRINOLOGY. 152:1300-1313.Full Text via DOI: 10.1210/en.2010-1029 PMID: 21285317
-
2011Central and Peripheral Endocannabinoids and Cognate Acylethanolamides in Humans: Association with Race, Adiposity, and Energy Expenditure. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 96:787-791.Full Text via DOI: 10.1210/jc.2010-2028 PMID: 21177788
-
2011Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. DIABETIC MEDICINE. 28:333-337.Full Text via DOI: 10.1111/j.1464-5491.2010.03074.x PMID: 21309842
-
2011Beta-cell preservationIs weight loss the answer?. The review of diabetic studies : RDS. 446-53.Full Text via DOI: 10.1900/RDS.2011.8.446 PMID: 22580726
-
2010An official American Thoracic Society Workshop report: obesity and asthma.. Proceedings of the American Thoracic Society. 325-35.Full Text via DOI: 10.1513/pats.200903-013ST PMID: 20844291
-
2010GIP: An Inconsequential Incretin or Not?. DIABETES CARE. 1691-1692.Full Text via DOI: 10.2337/dc10-0704 PMID: 20587731
-
2010Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study.. Current diabetes reports. 173-5.Full Text via DOI: 10.1007/s11892-010-0107-5 PMID: 20425579
-
2010Advances in the treatment of prediabetes. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM. 1:5-14.Full Text via DOI: 10.1177/2042018810366429 PMID: 23148144
-
2009Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 57:2011-2019.Full Text via DOI: 10.1111/j.1532-5415.2009.02484.x PMID: 19793357
-
2009Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. DIABETES OBESITY & METABOLISM. 11:978-986.Full Text via DOI: 10.1111/j.1463-1326.2009.01080.x PMID: 19614942
-
2009Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. CURRENT MEDICAL RESEARCH AND OPINION. 25:2361-2371.Full Text via DOI: 10.1185/03007990903156111 PMID: 19650752
-
2009Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 20:S309-S318.Full Text via DOI: 10.1016/j.ejim.2009.05.011 PMID: 19580950
-
2009Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus. AMERICAN JOURNAL OF MEDICINE. 122:11-24.Full Text via DOI: 10.1016/j.amjmed.2009.03.013 PMID: 19464424
-
2009Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. EXPERT OPINION ON PHARMACOTHERAPY. 503-512.Full Text via DOI: 10.1517/14656560802694713 PMID: 19191685
-
2009Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. DIABETES OBESITY & METABOLISM. 11:167-176.Full Text via DOI: 10.1111/j.1463-1326.2008.01016.x PMID: 19125778
-
2009Weight loss and diets: which diet works best?. Current diabetes reports. 35-6.PMID: 19192422
-
2009Expanding Treatment Options for Type 2 Diabetes The Old and the New. DIABETES EDUCATOR. 35:4S-11S.Full Text via DOI: 10.1177/0145721709331522 PMID: 19218561
-
2009Plasma Amyloid-beta Peptide Levels Correlate with Adipocyte Amyloid Precursor Protein Gene Expression in Obese Individuals. NEUROENDOCRINOLOGY. 90:383-390.Full Text via DOI: 10.1159/000235555 PMID: 19672057
-
2009Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 94:81-88.Full Text via DOI: 10.1210/jc.2008-1135 PMID: 18957505
-
2008Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.. Journal of the American Academy of Nurse Practitioners. 7-11.PMID: 19402254
-
2008Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. DIABETES OBESITY & METABOLISM. 10:931-938.Full Text via DOI: 10.1111/j.1463-1326.2007.00835.x PMID: 18093207
-
2008The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 372:595-600.Full Text via DOI: 10.1016/j.bbrc.2008.05.077 PMID: 18505678
-
2008Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.. Medscape journal of medicine. 171.PMID: 18769687
-
2008Amyloid precursor protein expression is upregulated in adipocytes in obesity. OBESITY. 16:1493-1500.Full Text via DOI: 10.1038/oby.2008.267 PMID: 18483477
-
2008Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 294:E1035-E1045.Full Text via DOI: 10.1152/ajpendo.00789.2007 PMID: 18413671
-
2008Effect of a polymorphism in the ND1 mitochondrial gene on human skeletal muscle mitochondrial function. OBESITY. 16:363-368.Full Text via DOI: 10.1038/oby.2007.40 PMID: 18239645
-
2008LAP-BAND or medical therapy for metabolic syndrome?. Current diabetes reports. 5-6.PMID: 18366991
-
2008Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. CURRENT DIABETES REVIEWS. 4:129-145.Full Text via DOI: 10.2174/157339908784220714 PMID: 18473760
-
2008Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.. The review of diabetic studies : RDS. 73-94.Full Text via DOI: 10.1900/RDS.2008.5.73 PMID: 18795210
-
2007Management of type 2 diabetes in treatment-naive elderly patients. DIABETES CARE. 30:3017-3022.Full Text via DOI: 10.2337/dc07-1188 PMID: 17878242
-
2007The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?. DIABETES & VASCULAR DISEASE RESEARCH. 237-40.PMID: 17907116
-
2007On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. CORONARY ARTERY DISEASE. 405-409.PMID: 17627191
-
2007Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? Commentary. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM. 450-451.Full Text via DOI: 10.1038/ncpendmet0512 PMID: 17457306
-
2007Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. CURRENT MEDICAL RESEARCH AND OPINION. 919-931.Full Text via DOI: 10.1185/030079906X162746 PMID: 17407649
-
2007Impaired fasting glucose and impaired glucose tolerance - Implications for care. DIABETES CARE. 30:753-759.Full Text via DOI: 10.2337/dc07-9920 PMID: 17327355
-
2007Metabolic syndrome: why the controversy?. CURRENT DIABETES REPORTS. 56-9.PMID: 17348123
-
2007The DREAM Trial: using ramipril and rosiglitazone to prevent diabetes.. CURRENT DIABETES REPORTS. 53-5.PMID: 17254518
-
2007Abdominal obesity and cardiovascular disease risk - The emerging role of the adipocyte. JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION. 2-10.PMID: 17474638
-
2006Islet dysfunction: An underlying defect in the pathophysiology of type 2 diabetes. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA. 35:6-11.PMID: 17424674
-
2006Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. LIFE SCIENCES. 79:1600-1605.Full Text via DOI: 10.1016/j.lfs.2006.05.011 PMID: 16750223
-
2006Insulin resistance increases PAI-1 in the heart. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 346:102-107.Full Text via DOI: 10.1016/j.bbrc.2006.05.078 PMID: 16750510
-
2006Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. HORMONE AND METABOLIC RESEARCH. 38:423-428.Full Text via DOI: 10.1055/s-2006-944546 PMID: 16823726
-
2006Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.. CURRENT DIABETES REPORTS. 47-54.PMID: 16522281
-
2006The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.. CURRENT DIABETES REPORTS. 45-6.PMID: 16522280
-
2005beta-cell function in mild type 2 diabetic patients - Effects of 6-month lowering with nateglinide. DIABETES CARE. 28:1132-1138.PMID: 15855578
-
2005The evolving role of inflammation in obesity and the metabolic syndrome.. CURRENT DIABETES REPORTS. 70-5.PMID: 15663921
-
2004Exaggerated insulin secretion in Pima Indians and African-Americans but higher insulin resistance in Pima Indians compared to African-Americans and Caucasians. DIABETIC MEDICINE. 21:1090-1095.Full Text via DOI: 10.1111/j.1464-5491.2004.01290.x PMID: 15384955
-
2004Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. METABOLISM-CLINICAL AND EXPERIMENTAL. 53:904-911.Full Text via DOI: 10.1016/j.metabol.2004.01.014 PMID: 15254885
-
2004Taste preferences and body weight changes in an obesity-prone population. AMERICAN JOURNAL OF CLINICAL NUTRITION. 79:372-378.PMID: 14985209
-
2003Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin-resistant and insulin-sensitive Pima Indians by differential display PCR. DIABETOLOGIA. 46:1567-1575.Full Text via DOI: 10.1007/s00125-003-1226-1 PMID: 14576983
-
2003Effect of a diabetic environment in utero on predisposition to type 2 diabetes. LANCET. 361:1861-1865.PMID: 12788573
-
2003Effects of improving insulin sensitivity on nontraditional cardiovascular risk factors in patients with type 2 diabetes.. CURRENT DIABETES REPORTS. 63-4.PMID: 12685440
-
2002Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. DIABETOLOGIA. 45:1584-1593.Full Text via DOI: 10.1007/s00125-002-0905-7 PMID: 12436343
-
2002
-
2002Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion.. CURRENT DIABETES REPORTS. 242-8.PMID: 12643180
-
2002Sex differences in the human brain's response to hunger and satiation. AMERICAN JOURNAL OF CLINICAL NUTRITION. 75:1017-1022.PMID: 12036808
-
2002UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates. MOLECULAR GENETICS AND METABOLISM. 75:369-373.PMID: 12051969
-
2002Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. ATHEROSCLEROSIS. 161:233-242.PMID: 11882337
-
2002
-
2002The quality of fat in the diet and its impact on insulin sensitivity.. CURRENT DIABETES REPORTS. 69-70.PMID: 15279020
-
2001Effect of satiation on brain activity in obese and lean women. OBESITY RESEARCH. 9:676-684.PMID: 11707534
-
2001Rapid acting insulinotropic agents: Restoration of early insulin secretion as a physiologic approach to improve glucose control. CURRENT PHARMACEUTICAL DESIGN. 1375-1397.PMID: 11472274
-
2001Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. MOVEMENT DISORDERS. 16:924-927.PMID: 11746624
-
2001Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. DIABETES. 50:1828-1833.PMID: 11473045
-
2001The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. DIABETOLOGIA. 929-945.PMID: 11484070
-
2001Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. OBESITY RESEARCH. 9:414-417.PMID: 11445664
-
2001Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 86:1930-1935.PMID: 11344187
-
2001Reduced skeletal muscle calpain-10 transcript level is due to a cumulative decrease in major isoforms. MOLECULAR GENETICS AND METABOLISM. 73:111-113.PMID: 11350192
-
2001Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians. MOLECULAR GENETICS AND METABOLISM. 72:231-238.Full Text via DOI: 10.1006/mgme.2001.3147 PMID: 11243729
-
2001Exaggerated pancreatic polypeptide secretion in Pima Indians: Can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?. METABOLISM-CLINICAL AND EXPERIMENTAL. 50:223-230.Full Text via DOI: 10.1053/meta.2001.20170 PMID: 11229433
-
2000Effects of an Ala54Thr polymorphism in the intestinal fatty acid-binding protein on responses to dietary fat in humans. JOURNAL OF LIPID RESEARCH. 41:2002-2008.PMID: 11108733
-
2000Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. DIABETOLOGIA. 43:1498-1506.PMID: 11151758
-
2000Relationship between birth weight and body composition, energy metabolism, and sympathetic nervous system activity later in life. OBESITY RESEARCH. 8:559-565.PMID: 11156431
-
2000A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. JOURNAL OF CLINICAL INVESTIGATION. 106:R69-R73.PMID: 11018080
-
2000Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. HYPERTENSION. 36:531-537.PMID: 11040231
-
2000Aerobic exercise training-induced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 48:1055-1061.PMID: 10983904
-
2000Palmitate oxidation rate and action on glycogen synthase in myoblasts from insulin-resistant subjects. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 279:E561-E569.PMID: 10950823
-
2000Insulin action and insulinemia are closely related to the fasting complement C3, hot not acylation stimulating protein concentration. DIABETES CARE. 23:779-785.PMID: 10840996
-
2000Differential brain responses to satiation in obese and lean men. DIABETES. 49:838-846.PMID: 10905495
-
2000Insulin increases leptin mRNA expression in abdominal subcutaneous adipose tissue in humans. MOLECULAR GENETICS AND METABOLISM. 70:19-26.PMID: 10833328
-
2000A shocking case of diabetic neuropathy. LANCET. 1560-1560.PMID: 10801209
-
2000Energy expenditure, fat oxidation, and body weight regulation: A study of metabolic adaptation to long-term weight change. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 85:1087-1094.PMID: 10720044
-
2000Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. AMERICAN JOURNAL OF EPIDEMIOLOGY. 151:190-198.PMID: 10645822
-
2000Ambulatory blood pressure after acute exercise in older men with essential hypertension. AMERICAN JOURNAL OF HYPERTENSION. 13:44-51.PMID: 10678270
-
2000Changes in plasma leptin and insulin action with resistive training in postmenopausal women. INTERNATIONAL JOURNAL OF OBESITY. 24:27-32.PMID: 10702747
-
2000Higher sedentary energy expenditure in patients with Huntington's disease. ANNALS OF NEUROLOGY. 47:64-70.PMID: 10632102
-
2000
-
2000Pro115GIn peroxisome proliferator-activated receptor-gamma and obesity. DIABETES CARE. 126-127.PMID: 10857984
-
1999Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. DIABETES. 48:2197-2203.PMID: 10535454
-
1999Regions of the human brain affected during a liquid-meal taste perception in the fasting state: a positron emission tomography study. AMERICAN JOURNAL OF CLINICAL NUTRITION. 70:806-810.PMID: 10539739
-
1999Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. OBESITY RESEARCH. 7:444-452.PMID: 10509601
-
1999The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. JOURNAL OF CLINICAL INVESTIGATION. 104:787-794.PMID: 10491414
-
1999Insulin receptor autophosphorylation in cultured myoblasts correlates to glucose disposal in Pima Indians. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 276:E990-E994.PMID: 10329994
-
1999Molecular scanning of the beta-3-adrenergic receptor gene in Pima Indians and Caucasians. DIABETES-METABOLISM RESEARCH AND REVIEWS. 15:175-180.PMID: 10441039
-
1999Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 96:4569-4574.PMID: 10200303
-
1999Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. DIABETES. 48:146-149.PMID: 9892236
-
1998Lower daily energy expenditure as measured by a respiratory chamber in subjects with spinal cord injury compared with control subjects. AMERICAN JOURNAL OF CLINICAL NUTRITION. 68:1223-1227.PMID: 9846850
-
1998The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. AMERICAN JOURNAL OF HYPERTENSION. 11:1405-1412.PMID: 9880120
-
1998Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism obesity in Pima Indians. HUMAN MOLECULAR GENETICS. 7:1431-1435.PMID: 9700198
-
1998Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. METABOLISM-CLINICAL AND EXPERIMENTAL. 47:1075-1082.PMID: 9751236
-
1998Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 83:2993-2996.PMID: 9709981
-
1998Plasma leptin concentrations: no difference between diabetic Pima Indians with and without nephropathy. DIABETOLOGIA. 861-862.PMID: 9686932
-
1998Postabsorptive respiratory quotient and insulin-stimulated glucose storage rate in nondiabetic Pima Indians are related to glycogen synthase fractional activity in cultured myoblasts. JOURNAL OF CLINICAL INVESTIGATION. 101:2251-2256.PMID: 9593781
-
1998Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians. PROCEEDINGS OF THE NUTRITION SOCIETY. 57:175-181.PMID: 9656318
-
1998An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. JOURNAL OF CLINICAL INVESTIGATION. 101:1757-1764.PMID: 9541507
-
1998Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians. AMERICAN JOURNAL OF HUMAN GENETICS. 62:659-668.PMID: 9497255
-
1998Acute and chronic resistive exercise increase urinary chromium excretion in men as measured with an enriched chromium stable isotope. JOURNAL OF NUTRITION. 128:73-78.PMID: 9430605
-
1997Relationship of the white blood cell count to body fat: role of leptin. BRITISH JOURNAL OF HAEMATOLOGY. 99:447-451.PMID: 9375771
-
1997Plasma leptin responses to fasting in Pima Indians. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 273:E644-E649.PMID: 9316457
-
1997Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 273:E276-E283.PMID: 9277380
-
1997Relationship between muscle sympathetic nerve activity and plasma leptin concentration. OBESITY RESEARCH. 5:338-340.PMID: 9285841
-
1997Identification of rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. JOURNAL OF CELLULAR BIOCHEMISTRY. 65:527-541.PMID: 9178102
-
1997Acute and prolonged administration of glucocorticoids (methylprednisolone) does not affect plasma leptin concentration in humans. INTERNATIONAL JOURNAL OF OBESITY. 21:327-330.PMID: 9130032
-
1997Familiar ty of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in pima Indians. AMERICAN JOURNAL OF HUMAN GENETICS. 60:651-656.PMID: 9042926
-
1997Relatively low plasma leptin concentrations precede weight gain in Pima Indians. NATURE MEDICINE. 3:238-240.PMID: 9018247
-
1997beta(3)-Adrenergic receptor gene variant and lipid metabolism in Pima Indians. DIABETOLOGIA. 123-124.PMID: 9028730
-
1996Effects of acute hyperinsulinemia on plasma leptin concentrations in insulin-sensitive and insulin-resistant Pima Indians. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 81:4418-4421.PMID: 8954052
-
1996Human primary myoblast cell cultures from non-diabetic insulin resistant subjects retain defects in insulin action. JOURNAL OF CLINICAL INVESTIGATION. 98:2346-2350.PMID: 8941652
-
1996Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. METABOLISM-CLINICAL AND EXPERIMENTAL. 45:1243-1247.PMID: 8843179
-
1996Resistive training increases insulin action in postmenopausal women. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 51:M199-M205.PMID: 8808989
-
1996Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men. JOURNAL OF APPLIED PHYSIOLOGY. 81:318-325.PMID: 8828680
-
1996Genomic structure and promoter analysis of the human obese gene. JOURNAL OF BIOLOGICAL CHEMISTRY. 271:3971-3974.PMID: 8626726
-
1995LEPTIN LEVELS IN HUMAN AND RODENT - MEASUREMENT OF PLASMA LEPTIN AND OB RNA IN OBESE AND WEIGHT-REDUCED SUBJECTS. NATURE MEDICINE. 1:1155-1161.PMID: 7584987
-
1995Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender.. OBESITY RESEARCH. 563-71.PMID: 8653533
-
1995RESISTIVE TRAINING INCREASES FAT-FREE MASS AND MAINTAINS RMR DESPITE WEIGHT-LOSS IN POSTMENOPAUSAL WOMEN. JOURNAL OF APPLIED PHYSIOLOGY. 79:818-823.PMID: 8567523
-
1995EFFECTS OF STRENGTH TRAINING ON MUSCLE HYPERTROPHY AND MUSCLE-CELL DISRUPTION IN OLDER MEN. INTERNATIONAL JOURNAL OF SPORTS MEDICINE. 16:378-384.PMID: 7591389
-
1995EFFECTS OF WEIGHT-LOSS ON NOREPINEPHRINE AND INSULIN LEVELS IN OBESE OLDER MEN. METABOLISM-CLINICAL AND EXPERIMENTAL. 44:438-444.PMID: 7723665
-
1995ENHANCED INSULIN SENSITIVITY AND LOWER WAIST-TO-HIP RATIO IN MASTER ATHLETES. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 268:E484-E490.PMID: 7900795
-
1994EFFECTS OF STRENGTH TRAINING ON BONE-MINERAL DENSITY - HORMONAL AND BONE TURNOVER RELATIONSHIPS. JOURNAL OF APPLIED PHYSIOLOGY. 77:1678-1684.PMID: 7836186
-
1994STRENGTH TRAINING INCREASES INSULIN ACTION IN HEALTHY 50-YR-OLD TO 65-YR-OLD MEN. JOURNAL OF APPLIED PHYSIOLOGY. 77:1122-1127.PMID: 7836113
-
1994EFFECTS OF STRENGTH TRAINING ON TOTAL AND REGIONAL BODY-COMPOSITION IN OLDER MEN. JOURNAL OF APPLIED PHYSIOLOGY. 77:614-620.PMID: 8002507
-
1994IMPAIRED INSULIN SENSITIVITY AND MAXIMAL RESPONSIVENESS IN OLDER HYPERTENSIVE MEN. HYPERTENSION. 23:320-324.PMID: 8125557
-
1994STRENGTH TRAINING INCREASES RESTING METABOLIC-RATE AND NOREPINEPHRINE LEVELS IN HEALTHY 50-YR-OLD TO 65-YR-OLD MEN. JOURNAL OF APPLIED PHYSIOLOGY. 76:133-137.PMID: 8175496
-
1993THE EFFECTS OF SINGLE AND SEQUENTIAL INSULIN INFUSIONS ON GLUCOSE DISPOSAL IN OLDER MEN. EXPERIMENTAL GERONTOLOGY. 28:381-391.PMID: 8224036
-
1993STRENGTH TRAINING INCREASES REGIONAL BONE-MINERAL DENSITY AND BONE REMODELING IN MIDDLE-AGED AND OLDER MEN. JOURNAL OF APPLIED PHYSIOLOGY. 74:2478-2484.PMID: 8335581
-
1993AN EPIDEMIOLOGIC TEST OF THE HYPERINSULINEMIA-HYPERTENSION HYPOTHESIS. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 76:544-548.PMID: 8445009
-
1992STRENGTH TRAINING ACCELERATES GASTROINTESTINAL TRANSIT IN MIDDLE-AGED AND OLDER MEN. MEDICINE & SCIENCE IN SPORTS & EXERCISE. 24:415-419.PMID: 1560736
-
1992BEHAVIORAL STRESS POTENTIATES THE BLOOD-PRESSURE EFFECTS OF A HIGH SODIUM-INTAKE. PSYCHOSOMATIC MEDICINE. 54:231-239.PMID: 1565758
-
1991SILENT-MYOCARDIAL-ISCHEMIA DURING REHABILITATION FOR CEREBROVASCULAR-DISEASE. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION. 59-62.PMID: 1985625
-
1988ELECTROPHYSIOLOGIC EFFECTS OF EPINEPHRINE IN HUMANS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 11:1235-1244.PMID: 2835408
Research
principal investigator on
- Pragmatic Evaluation of Events and Benefits of Lipid-lowering in Older Adults 2020 - 2027
- Glycemic Variability and Fluctuations in Cognitive Status in Adults with Type 1 Diabetes 2020 - 2023
- A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes 2019 - 2023
- A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus 2020 - 2021
- Development of novel biomarkers for the early diagnosis of T1D 2019 - 2021
- Natural History Study of the Development of Type 1 Diabetes 2015 - 2021
- Accelerating Solutions to Optimize Glycemic Control and Weight Management in Young Adults with Type 1 Diabetes 2017 - 2021
- Mitigating the Effects of the COVID-19 Pandemic on Unemployed Patients with T1D in the Orlando Area 2020 - 2021
- SuPAR levels in guiding the management of high-risk coronary artery disease (SuPAR BARI 2D) 2019 - 2020
- Investigating the Diagnostic Potential of Circulating Unmethylated Insulin DNA and Exosomal miRNAs in Subjects with Type 1 Diabetes and Residual β Cell Function 2018 - 2019
Background
Full Name
- Richard Edwin Pratley, MD
Education
- Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn
Residency
- University of Michigan, Ann Arbor, MI
Fellowship
- University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD
Board Certification
- American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com